AD/PD 2022 | Considering vascular pathologies when interpreting Alzheimer’s disease trial results

Gabriel Gold, MD, Faculty of Medicine, University Hospitals of Geneva, Geneva, Switzerland, stresses the importance of carefully interpreting the results of clinical trials on neurodegenerative diseases. Now that vascular damage is recognized as a critical correlate of cognitive function, it is important to understand that there are many confounding variabilities when interpreting results in trials following older people with neurodegenerative diseases. Vascular pathologies may be observed that have never been before and can represent a new therapeutic target and allow for future research. This interview took place at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases hosted in Barcelona, Spain.